Update: Systemic radiotherapy can cure lymphoma: A paradigm for other malignancies?

Gerald L Denardo, Sally J. DeNardo, Rod Balhorn

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.

Original languageEnglish (US)
Pages (from-to)383-397
Number of pages15
JournalCancer Biotherapy and Radiopharmaceuticals
Volume23
Issue number4
DOIs
StatePublished - Aug 1 2008

    Fingerprint

Keywords

  • Antibody
  • Non-Hodgkin's lymphoma
  • Radioimmunotherapy
  • Radionuclide
  • Radiotherapy
  • Solid cancers

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)
  • Oncology
  • Pharmacology

Cite this